prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. ender: F. Material: Total organ resection - left breast and axillary tissues. Unit in charge: (. Material received on: : Expected time of examination: up to 8 working days. Clinical diagnosis: Macroscopic breast'sized 24 x 19.5 x 5 cm removed with axillary tissues sized 10 x 7 x 2.5 cm and a skin flap of 24 x 12 and cm. 0 Tumour from sized the. description: Left 1.9 x 1.3 x 1.4 found in the subaurolar part, located 5.2 cm from the upper boundary, 2.8 cm from the base cm. skin. Metastatic lymph nodes 2 cm in length. Microscopic description: Carcinoma Foci of carcinoma ductale in situ DCIS detected within the tumour (cribrate and solid type with high nuclear atypia with comedo. ductale invasivum - NHG2 (3+2+1/6 mitoses/10 HPF - visual area 0.55 mm). necrosis, 5% of the tumour). Mamilla sine laesionibus. Glandular tissue showing lesions of the type mastopathia fibrosa. AXILLARY LYMPH NODES. Metastases carcinomatosae in lymphonodis (No IX/XV). Infiltratio capsulae lymphonodis et telae perinodalis. Histopathological ductale invasivum et ductale in situ mammae sinistrae. Invasive ductal and in situ ductal carcinoma of the IX/XV). left breasty. diagnosis: Carcinoma Metastases carcinomatosae in lymphonodis axillae (No IX/XV). Cancer metastases of the axillary lymph nodes (No. (NHG2, pTic, pN2a). page 2 / 2. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 protein stained with HercepTestTM by DAKO. Negative reaction in invasive cancerous cells ( Score = 1+ ).

expanded version (tokens=912) : 
 Histological classification: The report indicates that the patient has Luminal A subtype breast cancer. The report also mentions ductal carcinoma in situ (DCIS) within the tumor.

Nuclear grade/histological grade: The report states that the invasive ductal carcinoma is NHG2 (3+2+1/6 mitoses/10 HPF - visual area 0.55 mm). This indicates that the tumor is moderately differentiated.

Necrosis: The report states that there is necrosis present in 5% of the tumor.

Tumor infiltrating lymphocytes: There is no mention of tumor infiltrating lymphocytes in the report.

Lymphovascular invasion, calcification: There is no mention of lymphovascular invasion or calcification in the report.

Receptor status: The report indicates that estrogen and progesterone receptors are found in over 75% of neoplastic cell nuclei. The HER2 protein was negatively stained in invasive cancerous cells (Score = 1+).

Ancillary testing results: There is no mention of any other ancillary testing in the report.

In summary, the breast pathology report indicates that the patient has Luminal A subtype breast cancer with coexisting ductal carcinoma in situ (DCIS). The tumor is moderately differentiated with 5% necrosis. Estrogen and progesterone receptor-positive cells are found in over 75% of neoplastic cell nuclei, while HER2 protein is negatively stained (Score = 1+).

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=1048) : 
 The breast pathology report shows Luminal A subtype with ductal carcinoma in situ. The tumor is moderately differentiated with 5% necrosis and estrogen and progesterone receptor-positive cells found in over 75% of neoplastic cell nuclei. HER2 protein staining was negative (Score = 1+). There is no lymphovascular invasion or calcification, and no mention of tumor infiltrating lymphocytes or any ancillary testing.

